Bioabsorbable Magnesium Device Designed to Improve the Success of Vascular Access for Hemodialysis

Chronic Kidney Disease is a significant and costly health care challenge. More than 2 million people worldwide are receiving treatment with dialysis or kidney transplants, yet this may only represent 10 percent of those people needing treatment.

Most patients are treated with hemodialysis which requires vascular access. The preferred method of vascular access is the AV Fistula, but it has a failure rate of approximately 50 percent. There is an unmet clinical need for vascular access to treat kidney disease.

people graphic
37 Million

people in the U.S. are afflicted with chronic kidney disease

kidneys illustration
600 Thousand

patients have progressed to end‑stage renal disease

IV bag illustration
500 Thousand

patients in the U.S. are on hemodialysis

alert symbol
50 percent

AV Fistula, the preferred form of vascular access for hemodialysis, has a 50% failure rate


coil graphic

BioFlow Vascular Scaffold Device

nanoVascular has developed an innovative implantable device designed to greatly reduce fistula complications utilizing BioMg® 250, a patented absorbable magnesium alloy.